Asthma drug may help treat Alzheimer’s disease: Biogen’s antibody therapy awaits FDA approval

Around 50 million people are believed to be living with Alzheimer’s disease (AD)or other dementias worldwide. This number is more than the population of Columbia, according to the United Nations. Alzheimer’s disease is a neurological disorder that occurs when nerve cells in the brain die, resulting in memory loss and cognitive decline. Scientists have made some breakthroughs that could change the Alzheimer’s treatment landscape.

A laboratory study, published in the journal ACS Chemical Neuroscience, has suggested that asthma drug salbutamol may help treat Alzheimer’s disease. The researchers at Lancaster University in the United Kingdom found that salbutamol help prevent the formation of proteins associated with the disease.

Asthma drug shows promise in AD treatment

The brains of Alzheimer’s patients have plaques (made of beta-amyloid protein) between the nerve cells and clumps of fibers called neurofibrillary tangles (made up of tau protein) inside the cells. As drugs that clear the beta-amyloid protein did not slow down the progression of the disease, the researchers shifted their attention to tau.

They then tested the efficacy of 80 compounds in blocking the formation of the tau tangles. One of the compounds that show promising results was the hormone epinephrine, which helps stabilized tau proteins and successfully inhibited them from forming the tangles. However, since the body metabolizes epinephrine rapidly, the researchers started looking for drugs that have the same chemical structure as that of epinephrine and zeroed in on asthma drug salbutamol. Upon further testing, they found that salbutamol binds to tau molecules and prevents them from forming a nuclei, and hence reduces the possibility of other proteins to aggregate.

However, the researchers noted that their work is in the very early stages, and that further studies are needed to confirm whether or not salbutamol will be effective at treating Alzheimer’s disease in human patients. Further testing will be done on animal models of the disease, they added.

Biogen’s antibody therapy gets

Meanwhile, Biogen believes that its new antibody therapy could change the Alzheimer’s treatment landscape. The American multinational biotechnology company has completed the submission of a Biologics License Application (BLA) of its monoclonal antibody (mAb) aducanumab to the FDA for the treatment of Alzheimer’s disease. The drug, which helps clear amyloid plaques in the brain, is expected to be the first drug to reach the AD market.

However, some experts have expressed doubts about its approval from federal regulators due to lack of substantial evidence about the efficacy of the drug. While one study showed convincing clinical efficacy with the high-dose arm, another study failed to show the same pattern of target engagement or clinical efficacy.

But key opinion leaders (KOLs) said that PDA is unlikely to turn down aducanumab even if its benefit is modest, as there is no therapy that is truly efficacious in Alzheimer’s treatment. The experts noted that no drug has been approved in the past 17 years in this disease area.

In March 2020, Biogen started a new multicenter safety study of aducanumab named EMBARK, including Alzheimer’s patients who had previously participated in the aducanumab studies. The trial was scheduled to be completed in Q3 2023 but it has been halted due to the Covid-19 pandemic.

Asthma drug may help treat Alzheimer’s disease: Biogen’s antibody therapy awaits FDA approval

Up next

73 workers test positive for coronavirus at Herefordshire veg farm with 200 staff forced to isolate

Author

shalw

Tags

Leave a Reply Cancel reply

Beware! This food may up the risk of asthma or other respiratory issues in children

Weekly basal insulin shot can work as well as daily jab

Is chronic nervousness and worry affecting your life? Try Yoga to deal with anxiety

Charlie Sheen opens up about how he first reacted to HIV diagnosis

M53 horror as emergency services confirm ‘a number of casualties’ after grammar school bus of pupils flips on motorway – with emergency services still on the scene for rescue

Amol Rajan in tense clash with GB News boss Angelos Frangopoulos as he insists he is ‘appalled’ by Laurence Fox’s comments on Ava Evans – but confirms he hasn’t been sacked yet

Brigitte Macron ‘loves reading about Kate Middleton’ and British Royal Family who are ‘big sellers’ in France, experts tell PALACE CONFIDENTIAL

Heart-stopping moment Countess Bathurst is almost hit by car overtaking a lorry while she cycled along main road on her £10,000 Porsche e-bike during charity ride

Asthma drug may help treat Alzheimer’s disease: Biogen’s antibody therapy awaits FDA approval

Up next

Author

shalw

Tags

Leave a Reply Cancel reply

You May Also Like